1. Home
  2. SYRE vs CHE Comparison

SYRE vs CHE Comparison

Compare SYRE & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

SELL

Current Price

$82.77

Market Cap

7.6B

Sector

Health Care

ML Signal

SELL

CHE

Chemed Corp

SELL

Current Price

$497.76

Market Cap

6.8B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SYRE
CHE
Founded
2013
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
6.8B
IPO Year
2015
1994

Fundamental Metrics

Financial Performance
Metric
SYRE
CHE
Price
$82.77
$497.76
Analyst Decision
Strong Buy
Buy
Analyst Count
18
5
Target Price
$119.93
★ $571.60
AVG Volume (30 Days)
★ 1.4M
138.7K
Earning Date
11-03-2026
10-27-2026
Dividend Yield
N/A
★ 0.56%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 9.97
Revenue
N/A
★ $2,529,978,000.00
Revenue This Year
N/A
$7.56
Revenue Next Year
N/A
$6.05
P/E Ratio
★ N/A
$50.18
Revenue Growth
N/A
★ 4.06
52 Week Low
$21.01
$365.21
52 Week High
$110.18
$557.00

Technical Indicators

Market Signals
Indicator
SYRE
CHE
Relative Strength Index (RSI) 42.00 41.17
Support Level $82.86 $496.86
Resistance Level $94.10 $518.25
Average True Range (ATR) 4.63 10.57
MACD -0.13 -0.19
Stochastic Oscillator 33.91 25.73

Price Performance

Historical Comparison
SYRE
CHE

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

About CHE Chemed Corp

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Share on Social Networks: